Clinical Study of Balofloxacin on Infectious Enteritis and Assessment of the Fecal Drug Concentration and Intestinal Microbial Flora in Patients with Infectious Enteritis

  • OBANA Mitsuo
    Department of Internal Medicine, Kawasaki Municipal Hospital
  • IRIMAJIRI Shoichiro
    Department of Infectious Diseases, Sapporo City General Hospital
  • TOMIZAWA Isao
    Department of Infectious Diseases, Sapporo City General Hospital
  • TAKIZAWA Yoshihiko
    Department of Infectious Diseases, Sapporo City General Hospital
  • SAKAMOTO Yumiko
    Department of Infectious Diseases, Sapporo City General Hospital
  • NITTA Yoshiro
    Department of Infectious Diseases, Tokyo Metropolitan Toshima General Hospital
  • TSUNODA Takafumi
    Department of Infectious Diseases, Tokyo Metropolitan Toshima General Hospital
  • FUKUDA Hiroyuki
    Department of Infectious Diseases, Tokyo Metropolitan Toshima General Hospital
  • YAMAGUCHI Tsuyoshi
    Department of Infectious Diseases, Tokyo Metropolitan Komagome General Hospital
  • MASUDA Gohta
    Department of Infectious Diseases, Tokyo Metropolitan Komagome General Hospital
  • NEGISHI Masayoshi
    Department of Infectious Diseases, Tokyo Metropolitan Komagome General Hospital
  • AJISAWA Atsushi
    Department of Infectious Diseases, Tokyo Metropolitan Komagome General Hospital
  • MURATA Misako
    Department of Infectious Diseaes, Tokyo Metropolitan Bokutoh General Hospital
  • OHNISHI Kenji
    Department of Infectious Diseaes, Tokyo Metropolitan Bokutoh General Hospital
  • SAGARA Hiroko
    Department of Infectious Diseaes, Tokyo Metropolitan Bokutoh General Hospital
  • SAJIMA Yoshikiyo
    Department of Infectious Diseaes, Tokyo Metropolitan Bokutoh General Hospital
  • MATSUMOTO Fumio
    Department of Infectious Diseases, Department of Gastroenterology Department of Internal Medicine, Kanagawa Prefectural Midwives and Nurses Training School Hospital
  • IMAI Takero
    Department of Infectious Diseases, Department of Gastroenterology Department of Internal Medicine, Kanagawa Prefectural Midwives and Nurses Training School Hospital
  • SAKURAI Iwao
    Department of Infectious Diseases, Department of Gastroenterology Department of Internal Medicine, Kanagawa Prefectural Midwives and Nurses Training School Hospital
  • TAKAHASHI Takayuki
    Department of Infectious Diseases, Department of Gastroenterology Department of Internal Medicine, Kanagawa Prefectural Midwives and Nurses Training School Hospital
  • KATO Koji
    Department of Communicable Diseases, Department of Gastroerology, Nagoya City Higashi General Hospital
  • MORI Masamiki
    Department of Communicable Diseases, Department of Gastroerology, Nagoya City Higashi General Hospital
  • HOSODA Shiro
    Second Department of Internal Medicine, Shiga University of Medical Science
  • BAMBA Tadao
    Second Department of Internal Medicine, Shiga University of Medical Science
  • SASAKI Masaya
    Second Department of Internal Medicine, Shiga University of Medical Science
  • TATEWAKI Kenichi
    Second Department of Internal Medicine, Shiga University of Medical Science
  • FUSE Kenji
    Second Department of Internal Medicine, Shiga University of Medical Science
  • SAKUMOTO Hiroshi
    Second Department of Internal Medicine, Shiga University of Medical Science
  • IWASAKI Yoshiaki
    Second Department of Internal Medicine, Shiga University of Medical Science
  • OHKUBO Hideo
    Department of Communicable Diseases, Kyoto City Hospital
  • KIM Yong-ki
    Department of Communicable Diseases, Kyoto City Hospital
  • AKAO Mitsuru
    Department of Internal Medicine, Infectious Diseases Center, Osaka Municipal Momoyama Hospital
  • SAKAUE Yoshihiro
    Department of Internal Medicine, Infectious Diseases Center, Osaka Municipal Momoyama Hospital
  • TOJO Kaneko
    Department of Internal Medicine, Infectious Diseases Center, Osaka Municipal Momoyama Hospital
  • AMATSU Junko
    Department of Internal Medicine, Infectious Diseases Center, Osaka Municipal Momoyama Hospital
  • YOSHIDA Hideki
    Department of Internal Medicine, Infectious Diseases Center, Osaka Municipal Momoyama Hospital
  • YOSHIKAWA Kunio
    Second Department of Internal Medicine, Shiga University of Medical Science
  • AISAKA Tadakazu
    Department of Internal Medicine, Hiroshima City Funairi Hospital
  • MIKAMI Motoko
    Department of Internal Medicine, Hiroshima City Funairi Hospital
  • KURIMURA Osamu
    Second Department of Internal Medicine, Kure National Hospital
  • KAGAWA Kazunori
    Second Department of Internal Medicine, Kure National Hospital
  • MATSUBARA Yoshio
    Department of Internal Medicine, Kiyose Jogu Hospital
  • IMAGAWA Yatsuka
    Department of Environmental Microbiology, College of Environmental Health Azabu University
  • FUKUYAMA Masafumi
    Department of Environmental Microbiology, College of Environmental Health Azabu University
  • SAITO Makoto
    Foundation Association of Tokyo City Preventive Medicine

Bibliographic Information

Other Title
  • 感染性腸炎に対するBalo floxacinの臨床的研究および感染性腸炎患者における糞便中薬剤濃度と腸内細菌叢の検討
  • カンセンセイ チョウ エン ニ タイスル Balofloxacin ノ リンシ

Search this article

Abstract

The efficacy, safety and usefulness of balofloxacin (BLFX) for patients with acute infectious enteritis and the carriers mainly shigellosis, were investigated. The drug was administered at a daily dose of 200 mg twice a day for 3 days to patients with cholera, 7 days to patients with Salmonella enteritis and 5 days to patients with other conditions of infectious enteritis including shigellosis;<BR>1. The efficacy was analyzed in 89 of the 135 patients who received the administration (43 patients with shigellosis, 14 with Salmonella enteritis, 8 with enteropathogenic/enterotoxigenic Escherichia coli enteritis, 3 with cholera, 7 with enteritis with other pathogenic bacteria, 6 with polymicrobial infectious enteritis and 8 with acute enteritis that was pathogen-negative).<BR>2. In patients bearing symptoms and who thus could be analyzed for drug efficacy, the drug was markedly effective or effective 50/52 (96.2%).<BR>3. Bacteriologically, the drug was effective for Shigella spp. in 41 (100%) of 41, Salmonella spp. in 12 (85.7%) of 14, and enteropathogenic/enterotoxigenic Escherichia coli in 8 of 8 cases.<BR>4. Adverse effects were seen in 5/133 patients (3.8%) receiving the drug, including two cases of skin eruption, one of numbness of the hands, one of oral aphtha, and one of nausea. In patients for whom laboratory findings were available, 20/115 (17.4%) showed abnormalities, mainly elevations of GOT and/or GPT, but these were slight.<BR>5. In terms of subjective reports of usefulness, 51/82 (62.2%) were markedly satisfied, and 73/82 (89.0%) were either satisfied or markedly satisfied.<BR>6. The influence of administration of BLFX on fecal concentration and intestinal microbial flora was investigated in 2 patients with acute infectious enteritis. Results approximately equivalent to such flora levels in healthy subjects were obtained.<BR>These results suggest that BLFX is highly useful for infectious enteritis such as that caused by shigellosis.

Journal

  • Kansenshogaku Zasshi

    Kansenshogaku Zasshi 69 (9), 991-1006, 1995

    The Japanese Association for Infectious Diseases

Citations (1)*help

See more

References(13)*help

See more

Details

Report a problem

Back to top